Zebrafish model of amyloid light chain cardiotoxicity

regeneration versus degeneration

Shikha Mishra, Shaurya Joshi, Jennifer E. Ward, Eva P. Buys, Deepak Mishra, Deepa Mishra, Isabel Morgado, Sudeshna Fisch, Francesca Lavatelli, Giampaolo Merlini, Sharmila Dorbala, Calum A. MacRae, Ronglih Liao

Research output: Contribution to journalArticle

Abstract

Cardiac dysfunction is the most frequent cause of morbidity and mortality in amyloid light chain (AL) amyloidosis caused by a clonal immunoglobulin light chain (LC). Previously published transgenic animal models of AL amyloidosis have not recapitulated the key phenotype of cardiac dysfunction seen in AL amyloidosis, which has limited our understanding of the disease mechanisms in vivo, as well as the development of targeted AL therapeutics. We have developed a transgenic zebrafish model in which a λ LC derived from a patient with AL amyloidosis is conditionally expressed in the liver under the control of the Gal4 upstream activation sequence enhancer system. Circulating LC levels of 125 µg/ml in these transgenic zebrafish are comparable to median pathological serum LC levels. Functional analysis links abnormal contractile function with evidence of cellular and molecular proteotoxicity in the heart, including increased cell death and autophagy. However, despite pathological and functional phenotypes analogous to human AL, the lifespan of the transgenic fish is comparable to control fish without the expressed AL-LC transgene. Nuclear labeling experiments suggest increased cardiac proliferation in the transgenic fish, which can be counteracted by treatment with a small molecule proliferation inhibitor leading to increased zebrafish mortality because of cardiac apoptosis and functional deterioration. This transgenic zebrafish model provides a platform to study underlying AL disease mechanisms in vivo further. NEW & NOTEWORTHY Heart failure is a major cause of mortality in amyloid light (AL) amyloidosis, yet it has been difficult to model in animals. We report the generation of a transgenic zebrafish model for AL amyloidosis with pathological concentration of circulating human light chain protein that results in cardiac dysfunction. The light chain toxicity triggers regeneration in the zebrafish heart resulting in functional compensation early in life, but with age develops into cardiac dysfunction.

Original languageEnglish
Pages (from-to)H1158-H1166
JournalAmerican journal of physiology. Heart and circulatory physiology
Volume316
Issue number5
DOIs
Publication statusPublished - May 1 2019

Fingerprint

Zebrafish
Amyloid
Regeneration
Light
Amyloidosis
Fishes
Cardiotoxicity
Mortality
Animal Models
Immunoglobulin Light Chains
Phenotype
Genetically Modified Animals
Autophagy
Transgenes

Keywords

  • amyloidosis
  • in vivo model cardiovascular disease
  • proteotoxicity
  • transgenic zebrafish

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Zebrafish model of amyloid light chain cardiotoxicity : regeneration versus degeneration. / Mishra, Shikha; Joshi, Shaurya; Ward, Jennifer E.; Buys, Eva P.; Mishra, Deepak; Mishra, Deepa; Morgado, Isabel; Fisch, Sudeshna; Lavatelli, Francesca; Merlini, Giampaolo; Dorbala, Sharmila; MacRae, Calum A.; Liao, Ronglih.

In: American journal of physiology. Heart and circulatory physiology, Vol. 316, No. 5, 01.05.2019, p. H1158-H1166.

Research output: Contribution to journalArticle

Mishra, S, Joshi, S, Ward, JE, Buys, EP, Mishra, D, Mishra, D, Morgado, I, Fisch, S, Lavatelli, F, Merlini, G, Dorbala, S, MacRae, CA & Liao, R 2019, 'Zebrafish model of amyloid light chain cardiotoxicity: regeneration versus degeneration', American journal of physiology. Heart and circulatory physiology, vol. 316, no. 5, pp. H1158-H1166. https://doi.org/10.1152/ajpheart.00788.2018
Mishra, Shikha ; Joshi, Shaurya ; Ward, Jennifer E. ; Buys, Eva P. ; Mishra, Deepak ; Mishra, Deepa ; Morgado, Isabel ; Fisch, Sudeshna ; Lavatelli, Francesca ; Merlini, Giampaolo ; Dorbala, Sharmila ; MacRae, Calum A. ; Liao, Ronglih. / Zebrafish model of amyloid light chain cardiotoxicity : regeneration versus degeneration. In: American journal of physiology. Heart and circulatory physiology. 2019 ; Vol. 316, No. 5. pp. H1158-H1166.
@article{c10b0b8a50254f78b1d274b7147b2f21,
title = "Zebrafish model of amyloid light chain cardiotoxicity: regeneration versus degeneration",
abstract = "Cardiac dysfunction is the most frequent cause of morbidity and mortality in amyloid light chain (AL) amyloidosis caused by a clonal immunoglobulin light chain (LC). Previously published transgenic animal models of AL amyloidosis have not recapitulated the key phenotype of cardiac dysfunction seen in AL amyloidosis, which has limited our understanding of the disease mechanisms in vivo, as well as the development of targeted AL therapeutics. We have developed a transgenic zebrafish model in which a λ LC derived from a patient with AL amyloidosis is conditionally expressed in the liver under the control of the Gal4 upstream activation sequence enhancer system. Circulating LC levels of 125 µg/ml in these transgenic zebrafish are comparable to median pathological serum LC levels. Functional analysis links abnormal contractile function with evidence of cellular and molecular proteotoxicity in the heart, including increased cell death and autophagy. However, despite pathological and functional phenotypes analogous to human AL, the lifespan of the transgenic fish is comparable to control fish without the expressed AL-LC transgene. Nuclear labeling experiments suggest increased cardiac proliferation in the transgenic fish, which can be counteracted by treatment with a small molecule proliferation inhibitor leading to increased zebrafish mortality because of cardiac apoptosis and functional deterioration. This transgenic zebrafish model provides a platform to study underlying AL disease mechanisms in vivo further. NEW & NOTEWORTHY Heart failure is a major cause of mortality in amyloid light (AL) amyloidosis, yet it has been difficult to model in animals. We report the generation of a transgenic zebrafish model for AL amyloidosis with pathological concentration of circulating human light chain protein that results in cardiac dysfunction. The light chain toxicity triggers regeneration in the zebrafish heart resulting in functional compensation early in life, but with age develops into cardiac dysfunction.",
keywords = "amyloidosis, in vivo model cardiovascular disease, proteotoxicity, transgenic zebrafish",
author = "Shikha Mishra and Shaurya Joshi and Ward, {Jennifer E.} and Buys, {Eva P.} and Deepak Mishra and Deepa Mishra and Isabel Morgado and Sudeshna Fisch and Francesca Lavatelli and Giampaolo Merlini and Sharmila Dorbala and MacRae, {Calum A.} and Ronglih Liao",
year = "2019",
month = "5",
day = "1",
doi = "10.1152/ajpheart.00788.2018",
language = "English",
volume = "316",
pages = "H1158--H1166",
journal = "American Journal of Physiology - Heart and Circulatory Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "5",

}

TY - JOUR

T1 - Zebrafish model of amyloid light chain cardiotoxicity

T2 - regeneration versus degeneration

AU - Mishra, Shikha

AU - Joshi, Shaurya

AU - Ward, Jennifer E.

AU - Buys, Eva P.

AU - Mishra, Deepak

AU - Mishra, Deepa

AU - Morgado, Isabel

AU - Fisch, Sudeshna

AU - Lavatelli, Francesca

AU - Merlini, Giampaolo

AU - Dorbala, Sharmila

AU - MacRae, Calum A.

AU - Liao, Ronglih

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Cardiac dysfunction is the most frequent cause of morbidity and mortality in amyloid light chain (AL) amyloidosis caused by a clonal immunoglobulin light chain (LC). Previously published transgenic animal models of AL amyloidosis have not recapitulated the key phenotype of cardiac dysfunction seen in AL amyloidosis, which has limited our understanding of the disease mechanisms in vivo, as well as the development of targeted AL therapeutics. We have developed a transgenic zebrafish model in which a λ LC derived from a patient with AL amyloidosis is conditionally expressed in the liver under the control of the Gal4 upstream activation sequence enhancer system. Circulating LC levels of 125 µg/ml in these transgenic zebrafish are comparable to median pathological serum LC levels. Functional analysis links abnormal contractile function with evidence of cellular and molecular proteotoxicity in the heart, including increased cell death and autophagy. However, despite pathological and functional phenotypes analogous to human AL, the lifespan of the transgenic fish is comparable to control fish without the expressed AL-LC transgene. Nuclear labeling experiments suggest increased cardiac proliferation in the transgenic fish, which can be counteracted by treatment with a small molecule proliferation inhibitor leading to increased zebrafish mortality because of cardiac apoptosis and functional deterioration. This transgenic zebrafish model provides a platform to study underlying AL disease mechanisms in vivo further. NEW & NOTEWORTHY Heart failure is a major cause of mortality in amyloid light (AL) amyloidosis, yet it has been difficult to model in animals. We report the generation of a transgenic zebrafish model for AL amyloidosis with pathological concentration of circulating human light chain protein that results in cardiac dysfunction. The light chain toxicity triggers regeneration in the zebrafish heart resulting in functional compensation early in life, but with age develops into cardiac dysfunction.

AB - Cardiac dysfunction is the most frequent cause of morbidity and mortality in amyloid light chain (AL) amyloidosis caused by a clonal immunoglobulin light chain (LC). Previously published transgenic animal models of AL amyloidosis have not recapitulated the key phenotype of cardiac dysfunction seen in AL amyloidosis, which has limited our understanding of the disease mechanisms in vivo, as well as the development of targeted AL therapeutics. We have developed a transgenic zebrafish model in which a λ LC derived from a patient with AL amyloidosis is conditionally expressed in the liver under the control of the Gal4 upstream activation sequence enhancer system. Circulating LC levels of 125 µg/ml in these transgenic zebrafish are comparable to median pathological serum LC levels. Functional analysis links abnormal contractile function with evidence of cellular and molecular proteotoxicity in the heart, including increased cell death and autophagy. However, despite pathological and functional phenotypes analogous to human AL, the lifespan of the transgenic fish is comparable to control fish without the expressed AL-LC transgene. Nuclear labeling experiments suggest increased cardiac proliferation in the transgenic fish, which can be counteracted by treatment with a small molecule proliferation inhibitor leading to increased zebrafish mortality because of cardiac apoptosis and functional deterioration. This transgenic zebrafish model provides a platform to study underlying AL disease mechanisms in vivo further. NEW & NOTEWORTHY Heart failure is a major cause of mortality in amyloid light (AL) amyloidosis, yet it has been difficult to model in animals. We report the generation of a transgenic zebrafish model for AL amyloidosis with pathological concentration of circulating human light chain protein that results in cardiac dysfunction. The light chain toxicity triggers regeneration in the zebrafish heart resulting in functional compensation early in life, but with age develops into cardiac dysfunction.

KW - amyloidosis

KW - in vivo model cardiovascular disease

KW - proteotoxicity

KW - transgenic zebrafish

UR - http://www.scopus.com/inward/record.url?scp=85065580251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065580251&partnerID=8YFLogxK

U2 - 10.1152/ajpheart.00788.2018

DO - 10.1152/ajpheart.00788.2018

M3 - Article

VL - 316

SP - H1158-H1166

JO - American Journal of Physiology - Heart and Circulatory Physiology

JF - American Journal of Physiology - Heart and Circulatory Physiology

SN - 0363-6135

IS - 5

ER -